Annual report [Section 13 and 15(d), not S-K Item 405]

Significant Accounting Policies (Narrative) (Details)

v3.25.1
Significant Accounting Policies (Narrative) (Details)
 1 Months Ended 12 Months Ended
Oct. 31, 2024
USD ($)
Jul. 31, 2016
shares
Dec. 31, 2024
USD ($)
subsidiary
segment
shares
Dec. 31, 2023
USD ($)
Significant Accounting Policies        
Number of subsidiaries | subsidiary     0  
Number of operating segments | segment     1  
Restricted cash     $ 0 $ 750,000
Estimated useful life     5 years  
Deemed dividend for issuance of warrants $ 7,800,000      
Accumulated other comprehensive loss     $ 0  
Class A common stock and Class A preferred stock, rights to convert to number of common shares | shares     1,461  
Existing Warrants        
Significant Accounting Policies        
Amount of deemed dividend $ 7,800,000      
Assets held for sale, not discontinued operations        
Significant Accounting Policies        
Property, plant and equipment, held for sale     $ 1,200,000  
Fortress Biotech, Inc        
Significant Accounting Policies        
Percentage of fully diluted equity     2.50% 2.50%
Fortress Biotech, Inc | Class A Preferred Shares        
Significant Accounting Policies        
Preferred stock dividends issued (in shares) | shares   250,000    
Percentage of fully diluted equity   2.50%